DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,403,645 B2 Schildkraut Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,403,645 B2 Schildkraut Et Al USOO6403645B2 (12) United States Patent (10) Patent No.: US 6,403,645 B2 Schildkraut et al. (45) Date of Patent: Jun. 11, 2002 (54) ANTIDEPRESSANT EFFECT OF Hendley, “The Mechanism of Extraneuronal Transport of NOREPINEPHRINE UPTAKE 2 INHIBITORS Catecholamines in the Central Nervous System”, The AND COMBINED MEDICATIONS Mechanism of Neuronal and Extraneuronal Transport of INCLUDING THEM Catecholamines, Raven press, New York (1976). Inagaki et al., “Inhibitory Effect of (+)Threo-3,4-Dihy (75) Inventors: Joseph J. Schildkraut, Chestnut Hill; droxyphenylserine (DOPS) on Decarboxylation of (-)Thre John J. Mooney, Belmont, both of MA o-DOPS", Japan. J. Pharmacol., vol. 26, pp. 380-382, (US) (1976). Kato et al., “Studies on the Activity of ,-Threo-3,4-Dihy (73) Assignee: President and Fellows of Harvard droxyphenylserine (-DOPS) as a Catecholamine Precursor College, MA (US) in the Brain', Biochemical Pharmacology, vol. 36, No. 18, (*) Notice: Subject to any disclaimer, the term of this pp. 3051-3057. (1967). patent is extended or adjusted under 35 Katsube et al., “Development of L-threo-DOPS, a Norepi U.S.C. 154(b) by 0 days. nephrine Precursor Amine Acid', Yakugaku ZaSShi, vol. 144, No. 11, pp. 823–846, (1994). (21) Appl. No.: 09/811,235 Martel et al., “Comparison between uptake nd rCCT1: effects of catecholamides, metanephrines and corticoster (22) Filed: Mar. 16, 2001 one', Naunyn-Schmiedeberg's Arch Pharmacol, vol. 359, pp. 303-309, (1999). Related U.S. Application Data Maruyama et al., “A new metabolic pathway of -threo-3, (60) Provisional application No. 60/189,828, filed on Mar. 16, 4-dihydroxyphenylserine, a precursor amino acid of nore 2000. pinephrine, in the Studies by in vivo microdialysis”, J. (51) Int. Cl." ...................... A61K 31/195; A61K 31/55; Neural Transm, vol. 7, pp. 21-33, (1994). A61K 31/53; A61K 31/335; A61K 31/135 Maruyama et al., “The metabolism of ,-DOPA and -Th reo-3, 4-dihydroxyphenylserine and their effects on (52) U.S. Cl. ....................... 514/567; 514/211; 514/217; monoamines in the human brain: analysis of the intraven 514/242; 514/450; 514/653; 514/654 tricular fluid from parkinsonian patients”, Journal Of the (58) Field of Search ................................. 514/567, 653, Neurological Sciences, vol. 139, pp. 141-148, (1996). 514/217, 654, 211, 450, 242 Naoi et al., “L-Threo-3,4-Dihydroxyphenylserine (DOPS) Aldolase: A New Enzyme Cleaving DOPS Into Protocat (56) References Cited echualdehyde and Glycine”, Biochemical and Biophysical Research Communications, vol. 143, No. 2, pp. 482-488, U.S. PATENT DOCUMENTS (Mar. 1987). 3,723,514 A 3/1973 Hegedus et al. 4,480,109 A 10/1984 Ohashi et al. (List continued on next page.) 4,562.263 A 12/1985 Ohashi et al. 5,266,596 A 11/1993 Yokokawa et al. Primary Examiner William R. A. Jarvis 5,288.898 A 2/1994 Umezawa et al. (74) Attorney, Agent, or Firm-Fish & Richardson P.C. 5,739,387 A 4/1998 Oda et al. 5,864.041 A 1/1999 Oda et al. (57) ABSTRACT OTHER PUBLICATIONS Norepinephrine uptake 2 inhibitors (or their precursors) are administered to enhance the effect of norepinephrine Abstract from EP-112606-A (Jul. 1984). reuptake inhibitors and other antidepressants. The uptake 2 Abstract from J59199660 (Nov. 1984). inhibitor may be combined in a single medication with a Abstract from EP-528729-A+(Feb. 1993). norepinephrine reuptake inhibitor, Such as imipramine, Abstract from EP-576941-A+(Jan. 1994). desipramine, or reboxetine, in order to inhibit both uptake Bartholini et al., “The Stereoisomers of 3,4-Dihydroxyphe mechanisms. The norepinephrine uptake 2 inhibitors may nylserine as Precursors of Norepinephrine”, The Journal of also be combined with MAO inhibitors or with selective Pharmacology and Experimental Therapeutics, vol. 193, Serotonin reuptake inhibitors. Alternatively, the norepineph No. 3, pp. 523-532, (1974). rine uptake 2 inhibitors may be useful antidepressants in Bolden-Watson et al., “Blockade by Newly-Developed their own right, without the need for co-administration of Antidepressants of Biogenic Amine Uptake into Rat Brain other antidepressants. One class of norepinephrine uptake 2 Synaptosomes", Life Sciences, vol. 52, pp. 1023-1029, (Jan. inhibitors is normetanephrine (the O-methylated metabolite 1993). of norepinephrine) and normetanephrine precursors such as Creveling et al., “The Combined Use of a-Methyltryosine 3(4-hydroxy-3-methoxyphenyl)-serine (4H-3MePS ), par and Threo-Dihydroxyphenylserine-Selective Reduction of ticularly L-threo-3-(4-H-3 MePS) that are transported to the Dopamine Levels in the Central Nervous System”, Bio brain where they are converted into normetanephrine, chemical Pharmacology, vol. 17, pp. 65-70, Pergamon thereby enhancing the effect of other antidepressants. For Press, (1968). example, the invention enhances the antidepressant effect of Grundemann et al., “Molecular identification of the corti norepinephrine reuptake inhibitors. costerone-Sentsitive eXtraneuronal catecholamine trans porter', Nature Neuroscience, vol. 1, No. 5, (Sep. 1998). 32 Claims, 1 Drawing Sheet US 6,403,645 B2 Page 2 OTHER PUBLICATIONS Schildkraut et al., “Normetanephrine Excretion and Affec Porter et al., “(S)-Norepinephrine * in the Tissues of Mice tive State in Depressed Patients Treated with Imipramine”, and Rats Given Racemic Erythro-3, 4-Dihydroxyphe Amer. J. Psychiat, vol. 123, pp. 690–700, (Oct. 1966). nylserine (DOPS)”, Life Sciences, vol. 11, Part I, pp. Streich et al., “Expression of the extraneuronal monoamine 787-795, (1972). transporter (uptake) in human glioma cells”, Naunyn RuSS et al., “The extaneuronal transport mechanism for -Schmiedeberg's Arch Pharmacol, vol. 353, pp. 328-333, noradrenaline (uptake) avidly transports (1996). 1-methyl-4-phenylpyridinium (MPP")", Naunyn Yamamoto et al., “Effect of ,-Threo-3,4-dihydroxyphe -Schmiedeberg's Arch Pharmacol, vol. 346, pp. 158-165, nylserine Chronic Administration on Cerebrospinal Fluid (1992). and Plasma Free 3-Methoxy-4-hydroxy-phenylglycol Russ, et al., “The Extraneuronal Transporter for Monoamine Transmitters Exists in Cells Derived from Human Central Concentration in Patients with Parkinson's Disease”, Jour Nervous System Glia”, European Journal of Neuroscience, nal of Neurological Sciences, vol. 73, pp. 39–44, (1986). vol. 8, pp. 1256–1264, (1996). Maruyama et al, Clinical Neurology, No. 34,985–990, 1994. U.S. Patent Jun. 11, 2002 US 6,403,645 B2 " HO CH COOH d NH Sch 1. N-1 2 H2 NH2 -o- HO Decarboxylase HO OCH OCH 4-hydroxy-3-methoxyphenylserine Normetanephrine 4-H-3MePS Fig. 1 US 6,403,645 B2 1 2 ANTDEPRESSANT EFFECT OF norepinephrine and normetanephrine. However, by the NOREPINEPHRINE UPTAKE 2 INHIBITORS fourth week of treatment with desipramine, urinary levels of AND COMBINED MEDICATIONS norepinephrine and normetanephrine showed Statistically INCLUDING THEM Significant increases, and these increases were even more pronounced and Statistically significant after Six weeks of This application claims priority to provisional applica treatment with desipramine. Similar findings were observed in Studies of levels of norepinephrine in plasma during tion No. 60/189,828, filed Mar. 16, 2000. treatment with desipramine in these patients. (Plasma levels TECHNICAL FIELD of normetanephrine were not measured in these studies.) Without wishing to bind ourselves to a specific molecular This invention is in the general field of central nervous mechanism to the exclusion of other mechanisms, various System medications, particularly antidepressants. Substances Such as normetanephrine block uptake of nore pinephrine via uptake 2. Moreover, Such uptake 2 inhibitors BACKGROUND complement norepinephrine uptake 1 inhibitors, in that each Norepinephrine is released from presynaptic noradrener 15 Works independently to enhance extraneuronal norepineph gic neurons into the Synapse. One therapy for clinical rine levels in the brain. The invention therefore further depression is administration of drugs known as norepineph increases levels of norepinephrine present at the Synapse and rine reuptake inhibitors, Such as imipramine, desipramine, or Surrounding extraneuronal Spaces, thereby providing a more reboxetine, which inhibit the reuptake of norepinephrine rapid antidepressant effect for norepinephrine reuptake into the presynaptic neuron ("uptake 1), the main mecha inhibitors. nism of inactivating norepinephrine at the Synapse. Again, without wishing to bind ourselves exclusively to a Reuptake inhibition thus increases Synaptic norepinephrine mechanism of action, we note the following regarding the levels. Bolden-Watson and Richelson, Life Sciences, invention’s ability to reduce the time required for clinical 52:1023–1029 (1993), hereby incorporated by reference, antidepressant effects from the administration of norepi discloses a method for determining reuptake inhibition. 25 nephrine reuptake inhibitors. Reuptake inhibition at uptake Typically these drugs are administered chronically and there 1 Sites initially results in an increase of norepinephrine at the may be a significant delay, e.g. 4-6 weeks, between the onset Synapse. This results in the activation of presynaptic alpha of therapy and clinical improvement. adrenergic receptors as well as Somatodendritic alpha adrenergic receptors on noradrenergic neuronal cell bodies Other therapies feature the administration of other classes in the locus coeruleus (the nucleus containing norepineph of drugs, Such as monoamine oxidase (MAO) inhibitors or rine cell bodies in the brain), and the consequent feedback Selective Serotonin
Load more

Recommended publications
  • WHO Drug Information Vol. 12, No. 3, 1998
    WHO DRUG INFORMATION VOLUME 12 NUMBER 3 • 1998 RECOMMENDED INN LIST 40 INTERNATIONAL NONPROPRIETARY NAMES FOR PHARMACEUTICAL SUBSTANCES WORLD HEALTH ORGANIZATION • GENEVA Volume 12, Number 3, 1998 World Health Organization, Geneva WHO Drug Information Contents Seratrodast and hepatic dysfunction 146 Meloxicam safety similar to other NSAIDs 147 Proxibarbal withdrawn from the market 147 General Policy Issues Cholestin an unapproved drug 147 Vigabatrin and visual defects 147 Starting materials for pharmaceutical products: safety concerns 129 Glycerol contaminated with diethylene glycol 129 ATC/DDD Classification (final) 148 Pharmaceutical excipients: certificates of analysis and vendor qualification 130 ATC/DDD Classification Quality assurance and supply of starting (temporary) 150 materials 132 Implementation of vendor certification 134 Control and safe trade in starting materials Essential Drugs for pharmaceuticals: recommendations 134 WHO Model Formulary: Immunosuppressives, antineoplastics and drugs used in palliative care Reports on Individual Drugs Immunosuppresive drugs 153 Tamoxifen in the prevention and treatment Azathioprine 153 of breast cancer 136 Ciclosporin 154 Selective serotonin re-uptake inhibitors and Cytotoxic drugs 154 withdrawal reactions 136 Asparaginase 157 Triclabendazole and fascioliasis 138 Bleomycin 157 Calcium folinate 157 Chlormethine 158 Current Topics Cisplatin 158 Reverse transcriptase activity in vaccines 140 Cyclophosphamide 158 Consumer protection and herbal remedies 141 Cytarabine 159 Indiscriminate antibiotic
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain Et Al
    US 2012O190743A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0190743 A1 Bain et al. (43) Pub. Date: Jul. 26, 2012 (54) COMPOUNDS FOR TREATING DISORDERS Publication Classification OR DISEASES ASSOCATED WITH (51) Int. Cl NEUROKININ 2 RECEPTORACTIVITY A6II 3L/23 (2006.01) (75) Inventors: Jerald Bain, Toronto (CA); Joel CD7C 69/30 (2006.01) Sadavoy, Toronto (CA); Hao Chen, 39t. ii; C Columbia, MD (US); Xiaoyu Shen, ( .01) Columbia, MD (US) A6IPI/00 (2006.01) s A6IP 29/00 (2006.01) (73) Assignee: UNITED PARAGON A6IP II/00 (2006.01) ASSOCIATES INC., Guelph, ON A6IPI3/10 (2006.01) (CA) A6IP 5/00 (2006.01) A6IP 25/00 (2006.01) (21) Appl. No.: 13/394,067 A6IP 25/30 (2006.01) A6IP5/00 (2006.01) (22) PCT Filed: Sep. 7, 2010 A6IP3/00 (2006.01) CI2N 5/071 (2010.01) (86). PCT No.: PCT/US 10/48OO6 CD7C 69/33 (2006.01) S371 (c)(1) (52) U.S. Cl. .......................... 514/552; 554/227; 435/375 (2), (4) Date: Apr. 12, 2012 (57) ABSTRACT Related U.S. Application Data Compounds, pharmaceutical compositions and methods of (60) Provisional application No. 61/240,014, filed on Sep. treating a disorder or disease associated with neurokinin 2 4, 2009. (NK) receptor activity. Patent Application Publication Jul. 26, 2012 Sheet 1 of 12 US 2012/O190743 A1 LU 1750 15OO 1250 OOO 750 500 250 O O 20 3O 40 min SampleName: EM2OO617 Patent Application Publication Jul. 26, 2012 Sheet 2 of 12 US 2012/O190743 A1 kixto CFUgan <tro CFUgan FIG.2 Patent Application Publication Jul.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • WO 2012/044761 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date _ . 5 April 2012 (05.04.2012) WO 2012/044761 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/48 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (21) International Application Number: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, PCT/US201 1/053876 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, 29 September 201 1 (29.09.201 1) KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (25) Filing Language: English NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (26) Publication Langi English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, (30) Priority Data: ZM, ZW. 12/893,344 29 September 2010 (29.09.2010) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): UNI¬ kind of regional protection available): ARIPO (BW, GH, VERSITY OF NORTH CAROLINA AT WILMING¬ GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, TON [US/US]; 601 South College Road, Wilmington, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, NC 28403 (US).
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0136742 A1 Mickle Et Al
    US 20110136742A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0136742 A1 Mickle et al. (43) Pub. Date: Jun. 9, 2011 (54) ANTIDEPRESSANT PRODRUGS A 6LX 3/5.375 (2006.01) A 6LX 3/553 (2006.01) (76) Inventors: Travis Mickle, Coralville, IA (US); A6II 3/42 (2006.01) Wendy Hirschelman Severs, A6II 3/44 (2006.01) Blacksburg, VA (US) A6II 3/42 (2006.01) A6II 3/405 (2006.01) (21) Appl. No.: 12/280,190 A63L/36 (2006.01) A63/4985 (2006.01) (22) PCT Fled: Feb. 22, 2007 A6II 3/4409 (2006.01) A6II 3/554 (2006.01) A6II 3/405 (2006.01) S371 (c)(1), A6IP 25/24 (2006.01) (2), (4) Date: Sep. 14, 2010 A6IP 25/22 (2006.01) Related U.S. Application Data A6IP 25/18 (2006.01) (52) U.S. Cl. ........ 514/17.6: 514/564: 514/321; 514/217; (60) Provisional application No. 60/776,216, filed on Feb. 514/237.8: 514/211.13: 514/378: 514/354; 24, 2006. 514/376; 514/.424; 514/239.2: 514/.466; 514/250; 514/423: 514/419 Publication Classification (57) ABSTRACT (51) Int. Cl. A6 IK 38/06 (2006.01) The invention provides antidepressant prodrugs comprising A6 IK 38/05 (2006.01) an antidepressant conjugated to one or more amino acids. The A 6LX 3L/95 (2006.01) invention also relates to pharmaceutical compositions com A6 IK 3L/4525 (2006.01) prising an antidepressant prodrug, and to methods of prepar A6 IK3I/55 (2006.01) ing and using the same.
    [Show full text]
  • Development and Validation of a LC-MS/MS Method for Detection and Quantification of 18 Antidepressants in Whole Blood
    City University of New York (CUNY) CUNY Academic Works Student Theses John Jay College of Criminal Justice Spring 6-2019 Development and validation of a LC-MS/MS method for detection and quantification of 18 antidepressants in whole blood Linda Kim CUNY John Jay College, [email protected] How does access to this work benefit ou?y Let us know! More information about this work at: https://academicworks.cuny.edu/jj_etds/106 Discover additional works at: https://academicworks.cuny.edu This work is made publicly available by the City University of New York (CUNY). Contact: [email protected] Development and validation of a LC-MS/MS method for detection and quantification of 18 antidepressants in whole blood A Thesis Presented in Partial Fulfillment of the Requirements for the Degree of Master of Science in Forensic Science, John Jay College of Criminal Justice, City University of New York Linda Kim May 2019 Development and validation of a LC-MS/MS method for detection and quantification of 18 antidepressants in whole blood Linda Kim This Thesis has been presented to and accepted by the Office of Graduate Studies, John Jay College of Criminal Justice in Partial Fulfillment of the Requirements for the Degree of Master of Science in Forensic Science. Thesis Committee Thesis Advisor: Marta Concheiro-Guisan Second Reader: Shu-Yuan Cheng External Reader: Damon Borg i Acknowledgement I would like to thank Dr. Stripp for providing his laboratory for my research, and Dr. Borg and everyone in Cordant Laboratory for their guidance and support. I would like to thank Dr. Concheiro-Guisan for her time, patience, and information, and for making it possible to successfully complete this thesis.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,893,053 B2 Seed Et Al
    US0078.93053B2 (12) United States Patent (10) Patent No.: US 7,893,053 B2 Seed et al. (45) Date of Patent: Feb. 22, 2011 (54) TREATING PSYCHOLOGICAL CONDITIONS WO WO 2006/127418 11, 2006 USING MUSCARINIC RECEPTORM ANTAGONSTS (75) Inventors: Brian Seed, Boston, MA (US); Jordan OTHER PUBLICATIONS Mechanic, Sunnyvale, CA (US) Chau et al. (Nucleus accumbens muscarinic receptors in the control of behavioral depression : Antidepressant-like effects of local M1 (73) Assignee: Theracos, Inc., Sunnyvale, CA (US) antagonist in the porSolt Swim test Neuroscience vol. 104, No. 3, pp. 791-798, 2001).* (*) Notice: Subject to any disclaimer, the term of this Lind et al. (Muscarinic acetylcholine receptor antagonists inhibit patent is extended or adjusted under 35 chick Scleral chondrocytes Investigative Ophthalmology & Visual U.S.C. 154(b) by 726 days. Science, vol.39, 2217-2231.* Chau D., et al., “Nucleus Accumbens Muscarinic Receptors in the (21) Appl. No.: 11/763,145 Control of Behavioral Depression: Antidepressant-like Effects of Local M1 Antagonists in the Porsolt Swin Test.” Neuroscience, vol. (22) Filed: Jun. 14, 2007 104, No. 3, Jun. 14, 2001, pp. 791-798. Bechtel, W.D., et al., “Biochemical pharmacology of pirenzepine. (65) Prior Publication Data Similarities with tricyclic antidepressants in antimuscarinic effects only.” Arzneimittelforschung, vol. 36(5), pp. 793-796 (May 1986). US 2007/O293480 A1 Dec. 20, 2007 Chau, D.T. et al., “Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local Related U.S. Application Data Mantagonist in the Porsolt Swim test.” Neuroscience, vol. 104(3), (60) Provisional application No.
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • Gps' Drug Treatment for Depression by Patients' Educational Level
    RESEARCH GPs’ drug treatment for depression by patients’ educational level: registry- based study Anneli Borge Hansen, MD1,2*, Valborg Baste, MSc. Statistics, PhD1, Oystein Hetlevik, MD, PhD1,2, Inger Haukenes, MSc. Philosophy, PhD1,2, Tone Smith- Sivertsen, MD, PhD1,3, Sabine Ruths, MD, PhD1,2 1Research Unit for General Practice, NORCE Norwegian Research Centre, Bergen, Norway; 2Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway; 3Division of Psychiatry, Haukeland University Hospital, Bergen, Norway Abstract Background: Antidepressant drugs are often prescribed in general practice. Evidence is conflicting on how patient education influences antidepressant treatment. Aim: To investigate the association between educational attainment and drug treatment in adult patients with a new depression diagnosis, and to what extent sex and age influence the association. Design & setting: A nationwide registry- based cohort study was undertaken in Norway from 2014– 2016. Method: The study comprised all residents of Norway born before 1996 and alive in 2015. Information was obtained on all new depression diagnoses in general practice in 2015 (primary care database) and data on all dispensed depression medication (Norwegian Prescription Database [NorPD]) 12 months after the date of diagnosis. Independent variables were education, sex, and age. Associations with drug treatment were estimated using a Cox proportional hazard model and performed separately for sex. *For correspondence: ahan@ Results: Out of 49 967 patients with new depression (61.6% women), 15 678 were dispensed drugs norceresearch. no (30.4% women, 33.0% men). Highly educated women were less likely to receive medication (hazard ratio [HR] = 0.93; 95% confidence interval [CI] = 0.88 to 0.98) than women with low education.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]